AI for science · Landscape

Drug discovery has taken 84% of Europe’s AI-for-science funding since 2020

VC raised since 2020 by European companies in each field: 377 in drug discovery, 255 in engineering, 67 in materials

AI × drug discovery$13B · 84%

Isomorphic Labs$7.7B

acq.

Exscientia$625M

Owkin$303M

bit.bio$250M

Huma$243M

92 more$237M

Boltz$125M

Aqemia$116M

Cradle$103M

acq.

Chemify$98M

Nuritas$85M

Causaly$77M

Deciphex$71M

Healx$69M

Lifebit$68M

Cyted$66M

Quibim$64M

AI × engineering10%

PhysicsX$487M

71 more$122M

Optics11$79M

I-care$74M

Tacto$61M

DTE$41M

AI × materials6%

CuspAI$580M

15

Source: Dealroom.co, 9 November 2026. VC rounds 2020 to 9 November 2026; founding or HQ in Europe; mature companies excluded. Company counts include unfunded companies. “acq.” marks a company since acquired (Exscientia by Recursion, InstaDeep by BioNTech); its funding still counts. Huma is tagged AI drug discovery but sells a digital health platform.